Neurelis debuts seizure awareness campaign as it waits for FDA nod

Neurelis' first awareness campaign uses a split home screen to show a typical family day at the park with, and without, seizures. (Neurelis)

As Neurelis awaits an FDA decision on its flagship drug, the company has launched its first seizure awareness campaign.

Neurelis is hoping for an approval for nasal spray Valtoco to treat epilepsy patients six years of age and older who experience cluster or acute repetitive seizures. The drug is a rescue medicine that can stop seizures.

The campaign “Let’s Talk Seizures” looks to “revive” the discussion around the fact that some people with epilepsy who take anti-epileptic drugs still get seizures, Erin Adams, Neurelis' vice president of strategic marketing and portfolio planning, said.

Free Amazon Webinar

Performing end to end real-world evidence generation in the cloud with traceability and transparency- a Sanofi journey

In this webinar you will hear about Sanofi’s journey and experience in building an industrialized big data & analytics platform in the cloud that handles billions of rows of RWD data with complete data traceability, security, and supports both traditional and advanced analytics for day to day evidence generation (RWE).

“The unpredictability is the crux of what you see in this campaign. Raising discussion points is our objective here—what do you do when seizures happen and how can you be prepared to address this unpredictability? We want to re-raise awareness around the need for a seizure action plan or a seizure response plan,” she said.

RELATED: Sunovion highlights epilepsy heroes in reupped awareness campaign

The Centers for Disease Control and Prevention reported recently that 56% of patients who take anti-epilepsy meds still experience seizures.

Neurelis’ Valtoco would be the third drug on market that works as a rescue medicine for people with epilepsy to use during seizures. The first approved was Bausch Health’s Diastat, and while it has proven effective at stopping seizures, it is a rectal gel delivered via syringe, which causes some people to shy away from its use. The second, UCB's Nayzilam, was approved last week as the first inhaled rescue med for seizure clusters.

Besides the physical danger and potential damage from prolonged seizures, people who have a history of them also face a psychological impact, according to Adams. 

“This population has a high co-morbidity for anxiety and depression,” Adams said, noting that while it could be related to the epilepsy, these patients also go “through some pretty severe traumas and have a lot of anxiety provoking what-ifs hanging over their heads.”

RELATED: BioMarin expands genetic seizure testing program for kids

The digital campaign will include social media influencers as well as epilepsy foundation partners and professional societies. While the campaign is aimed at the entire epilepsy community, Neurelis specifically wants to reach patients who have a propensity for that kind of seizure activity as well as the healthcare providers who treat them.

The FDA previously granted Neurelis an orphan drug designation for Valtoco in November 2015 and a fast-track designation in December 2016. In April, the company announced five new executive hires to support the anticipated launch.

Editor's Note: The story was updated to reflect UCB's Nayzilam approval May 20 as the first inhaled rescue medicine for epilepsy.

Suggested Articles

Nearly four decades after it was approved, the FDA has ordered that heartburn drug Zantac and its generics be removed from the market.

In a non-randomized study in China, Avigan cleared virus after a median 4 days, significantly shorter than the 11 days observed for AbbVie's Kaletra.

Pfizer's 1.1-million-square-foot sterile injectables plant in Visakhapatnam has been criticized by the FDA for poor quality testing.